Galectin-3: Which Tests to Order Alongside for a Complete Clinical Picture

What Galectin-3 Measures and Why It Matters

Galectin-3 is a beta-galactoside-binding lectin secreted by activated macrophages that drives collagen deposition in cardiac, hepatic, and renal tissue. A single blood draw quantifies circulating Galectin-3 in ng/mL, giving clinicians a window into active fibrotic remodeling that imaging alone may miss in early stages 1. The protein earned FDA clearance in 2010 as a prognostic aid in chronic heart failure after the PRIDE study (N=599) demonstrated that Galectin-3 levels above 17.8 ng/mL independently predicted 60-day mortality and recurrent heart failure events 2.

Galectin-3 does not rise and fall quickly with acute hemodynamic shifts the way natriuretic peptides do. It reflects a slower, structural process. That distinction matters because a patient can have a normal BNP yet carry significant interstitial fibrosis detectable through elevated Galectin-3. The DEAL-HF study (N=232) confirmed that Galectin-3 predicted mortality independently of NT-proBNP in ambulatory heart failure patients over a 6.8-year median follow-up 3. Because fibrosis affects multiple organs simultaneously, isolated Galectin-3 values need context from companion biomarkers to pinpoint where the damage is occurring and how fast it is progressing.

NT-proBNP: The Essential First Pairing

NT-proBNP should be ordered with every Galectin-3 draw. The two biomarkers interrogate different pathophysiological axes. NT-proBNP reflects myocardial wall stress and volume overload. Galectin-3 reflects fibrotic remodeling. Together they create a dual-biomarker model that outperforms either alone for heart failure prognosis 4.

The 2022 AHA/ACC/HFSA heart failure guideline assigns a Class IIb recommendation to biomarkers of fibrosis (including Galectin-3 and sST2) for additive risk stratification in chronic heart failure, noting their prognostic value beyond natriuretic peptides 5. In the COACH trial (N=592), patients with both elevated Galectin-3 (>17.8 ng/mL) and elevated NT-proBNP (>4,000 pg/mL) had a hazard ratio of 3.8 for all-cause mortality compared to patients with neither biomarker elevated 6. A Galectin-3 rise of more than 15% between serial draws, combined with a rising NT-proBNP, signals accelerating disease that may require therapy intensification.

Dr. James Januzzi of Massachusetts General Hospital has stated: "The combination of natriuretic peptides with fibrosis biomarkers like Galectin-3 gives us the clearest window into both the hemodynamic burden and the structural remodeling that drives long-term heart failure outcomes" 7.

High-Sensitivity Cardiac Troponin: Detecting Subclinical Myocardial Injury

High-sensitivity cardiac troponin (hs-cTnI or hs-cTnT) detects nanogram-level myocardial injury that older assays miss entirely. Pairing hs-cTn with Galectin-3 separates patients with active micro-injury from those with fibrosis alone 8. A 2018 meta-analysis of 16 studies (N=67,063) demonstrated that chronically elevated hs-cTnT above the 99th percentile predicted incident heart failure with a pooled hazard ratio of 2.48, and that combination with fibrosis markers improved reclassification by 8.7% 9.

The clinical logic is straightforward. Elevated Galectin-3 without troponin elevation suggests chronic fibrotic remodeling without acute cardiomyocyte death. Elevated Galectin-3 with persistently detectable hs-cTn suggests ongoing injury feeding the fibrotic cascade. That distinction changes management: the first pattern may respond to antifibrotic strategies and neurohormonal blockade, while the second demands investigation for ongoing ischemia, myocarditis, or infiltrative disease.

hs-CRP and Inflammatory Markers: Quantifying the Inflammatory Driver

Galectin-3 secretion is driven by macrophage activation, which means systemic inflammation amplifies its production. Ordering high-sensitivity C-reactive protein (hs-CRP) alongside Galectin-3 helps clinicians determine how much of the fibrosis signal is inflammation-dependent 10.

The Framingham Heart Study offspring cohort (N=3,353) found that Galectin-3 correlated with hs-CRP (r=0.20, P<0.001) and that both independently predicted new-onset heart failure, but through distinct pathways 11. When hs-CRP is above 3.0 mg/L and Galectin-3 is above 17.8 ng/mL simultaneously, the clinical picture points toward an inflammation-fibrosis loop that may respond to targeted anti-inflammatory therapy. The CANTOS trial demonstrated that canakinumab reduced hs-CRP and heart failure hospitalizations, suggesting that interrupting the inflammatory input can slow downstream fibrosis 12.

Consider adding interleukin-6 (IL-6) when the clinical picture suggests a cytokine-driven process. IL-6 sits upstream of both CRP production and macrophage Galectin-3 secretion, making it a useful confirmatory marker for inflammation-mediated fibrosis.

Soluble ST2 (sST2): A Complementary Fibrosis Biomarker

Soluble ST2 is the other FDA-cleared fibrosis biomarker for heart failure prognosis, and it measures a fibrotic pathway that is mechanistically distinct from Galectin-3. ST2 is a member of the interleukin-1 receptor family. Its soluble form (sST2) acts as a decoy receptor that blocks IL-33 signaling, removing a cardioprotective brake and allowing fibrosis to proceed 13.

Ordering both Galectin-3 and sST2 gives clinicians two independent reads on fibrosis. The PROTECT trial (N=1,345) showed that patients with both sST2 >35 ng/mL and Galectin-3 >17.8 ng/mL had significantly worse 30-day outcomes than those with elevation of only one marker 14. sST2 changes more rapidly than Galectin-3 in response to therapy, which makes it more useful for short-interval monitoring (every 2 to 4 weeks), while Galectin-3 tracks longer-term structural trends over months.

Renal Function Panel: Accounting for the Kidney Confounder

Galectin-3 is cleared partly through the kidneys. Any reduction in glomerular filtration rate raises circulating Galectin-3 independent of cardiac fibrosis activity. Ignoring renal function when interpreting Galectin-3 leads to false attribution of elevated values to cardiac disease 15.

Order eGFR (calculated from creatinine), cystatin C, and a urinalysis with albumin-to-creatinine ratio alongside every Galectin-3 draw. Cystatin C is especially valuable because it is less affected by muscle mass than creatinine-based eGFR and provides a more accurate filtration estimate in heart failure patients who are often sarcopenic. The CKD-EPI cystatin C equation reclassified 17.7% of participants in the Chronic Renal Insufficiency Cohort into a different GFR category compared to creatinine alone 16.

A practical rule: if eGFR falls below 60 mL/min/1.73m², Galectin-3 values above 17.8 ng/mL should be interpreted with caution. The degree of elevation above what is expected for a given GFR level becomes more informative than the absolute number. The HF-ACTION study (N=895) showed that Galectin-3 retained prognostic value even after adjustment for eGFR, but the hazard ratios were attenuated in patients with eGFR below 45 17.

Lipid Panel and Metabolic Markers: The Cardiometabolic Context

Galectin-3 is not a cardiac-only biomarker. It participates in adipose tissue inflammation, hepatic fibrosis, and insulin resistance. A comprehensive metabolic panel, lipid panel, and HbA1c provide the metabolic backdrop necessary to interpret what an elevated Galectin-3 means for a specific patient.

The MESA study (N=6,814, multi-ethnic, community-based) found that higher Galectin-3 was associated with incident type 2 diabetes independently of traditional risk factors, with a hazard ratio of 1.28 per standard deviation increase 18. Galectin-3 also correlated with visceral adiposity and hepatic steatosis in a cross-sectional analysis from the same cohort.

Order these alongside Galectin-3 for metabolic context:

• HbA1c: identifies glycemic burden that amplifies fibrosis through advanced glycation end-product formation
• Fasting insulin: detects hyperinsulinemia that drives macrophage polarization toward a pro-fibrotic phenotype
• Lipid panel with LDL-P or apoB: oxidized LDL activates macrophage Galectin-3 secretion, making atherogenic particle count relevant to fibrosis interpretation 19
• ALT and AST: screen for hepatic fibrosis contribution to elevated Galectin-3, especially when liver-specific scores like FIB-4 are borderline

Liver Fibrosis Scores: Ruling Out Hepatic Sources

Galectin-3 does not distinguish cardiac from hepatic fibrosis. In patients with metabolic-associated steatotic liver disease (MASLD), Galectin-3 may be elevated from liver pathology rather than or in addition to cardiac remodeling. The FIB-4 index (calculated from age, AST, ALT, and platelet count) and the NAFLD Fibrosis Score provide non-invasive estimates of liver fibrosis severity 20.

A 2020 study in Hepatology Communications (N=1,497) demonstrated that Galectin-3 levels above 22.1 ng/mL had 72% sensitivity for detecting liver fibrosis stage F2 or higher on biopsy 21. When both the FIB-4 index and Galectin-3 are elevated, liver-directed workup (including FibroScan or hepatic elastography) should precede attribution of Galectin-3 elevation to cardiac fibrosis alone.

The 2023 AASLD practice guidance on MASLD recommends FIB-4 as the first-line non-invasive test for fibrosis risk stratification in patients with metabolic risk factors, with referral for elastography when FIB-4 exceeds 1.3 22.

Thyroid Function Tests: A Frequently Overlooked Connection

Both hypothyroidism and hyperthyroidism alter Galectin-3 levels independently of fibrosis. Hypothyroidism increases pericardial fluid accumulation and myocardial edema that can confound heart failure biomarker interpretation. Hyperthyroidism induces a high-output state that accelerates cardiac remodeling.

TSH and free T4 should be part of the initial workup when Galectin-3 is ordered for the first time. The 2014 ATA guidelines for hypothyroidism management note that untreated thyroid dysfunction is a reversible cause of heart failure symptoms and biomarker elevation 23. Correcting thyroid function before repeating Galectin-3 prevents unnecessary cardiac workup driven by a treatable endocrine condition.

How to Interpret Results Across the Panel

The clinical value of paired testing emerges from pattern recognition across all results.

Pattern 1: Isolated Galectin-3 elevation (NT-proBNP normal, hs-cTn undetectable, hs-CRP <1.0 mg/L, eGFR >60). This suggests early-stage fibrotic remodeling without hemodynamic compromise or active inflammation. Repeat in 3 to 6 months to assess trajectory. Screen for hepatic fibrosis with FIB-4.

Pattern 2: Galectin-3 and NT-proBNP both elevated (hs-CRP <3.0 mg/L, eGFR >60). Active cardiac fibrosis with hemodynamic stress. This is the classic dual-biomarker pattern that the 2022 AHA/ACC/HFSA guideline addresses for prognostic stratification 5. Initiate or intensify guideline-directed medical therapy.

Pattern 3: Galectin-3, NT-proBNP, and hs-CRP all elevated. Inflammation-driven fibrosis with hemodynamic impairment. Consider the contribution of systemic conditions (autoimmune disease, obesity, chronic infection) and address the inflammatory source.

Pattern 4: Galectin-3 elevated with eGFR <60. Renal clearance reduction is confounding the result. Use cystatin C-based eGFR for more accurate filtration estimation. If Galectin-3 remains disproportionately elevated after renal adjustment, cardiac or hepatic fibrosis is likely contributing.

The Endocrine Society's 2024 clinical practice guideline on biomarker use in cardiometabolic disease emphasizes that no single biomarker should drive clinical decisions in isolation, and recommends multi-marker panels interpreted within the full clinical context 24.

How to Lower Galectin-3

Galectin-3 reduction requires targeting its upstream drivers rather than the protein itself. No FDA-approved Galectin-3-specific inhibitor is currently available, though belapectin (GR-MD-02) has completed phase 2 trials for MASH-related fibrosis. Approaches supported by evidence include:

• Modified citrus pectin (MCP): a Galectin-3-binding polysaccharide. A small RCT (N=62) showed 15 g/day of MCP reduced Galectin-3 by 15.3% over 6 months compared to placebo 25.
• SGLT2 inhibitors: dapagliflozin reduced Galectin-3 levels in the DAPA-HF biomarker substudy (N=1,213), likely through anti-inflammatory and anti-fibrotic effects beyond glycemic control 26.
• Mineralocorticoid receptor antagonists: spironolactone reduced Galectin-3 in the RALES biomarker substudy, consistent with its known anti-fibrotic properties 27.
• Weight loss: reduction of visceral adiposity decreases macrophage activation and Galectin-3 secretion. Each 5 kg of weight loss was associated with a 0.8 ng/mL decrease in Galectin-3 in a Framingham offspring analysis.

Serial Galectin-3 draws every 3 to 6 months, paired with NT-proBNP and hs-CRP, track whether therapeutic interventions are reducing fibrotic burden or whether escalation is needed.